These compounds may interact with:
Nuclear receptor subfamily 1 group I member 2
Potentially involved in: malaria; carcinoma; cholestasis; cancer; leber congenital amaurosis; inflammatory bowel disease; liver disease; androgen insensitivity syndrome; cerebrotendinous xanthomatosis; primary sclerosing cholangitis; bilirubin metabolic disorder; adenocarcinoma; barrett esophagus; diabetes mellitus; esophageal neoplasms; fatty liver; hepatomegaly; female infertility; neonatal jaundice; obesity
Disease data sourced from Pharos.